mdl-100907 and Calcinosis

mdl-100907 has been researched along with Calcinosis* in 1 studies

Other Studies

1 other study(ies) available for mdl-100907 and Calcinosis

ArticleYear
5-HT(2B) antagonism arrests non-canonical TGF-β1-induced valvular myofibroblast differentiation.
    Journal of molecular and cellular cardiology, 2012, Volume: 53, Issue:5

    Transforming growth factor-β1 (TGF-β1) induces myofibroblast activation of quiescent aortic valve interstitial cells (AVICs), a differentiation process implicated in calcific aortic valve disease (CAVD). The ubiquity of TGF-β1 signaling makes it difficult to target in a tissue specific manner; however, the serotonin 2B receptor (5-HT(2B)) is highly localized to cardiopulmonary tissues and agonism of this receptor displays pro-fibrotic effects in a TGF-β1-dependent manner. Therefore, we hypothesized that antagonism of 5-HT(2B) opposes TGF-β1-induced pathologic differentiation of AVICs and may offer a druggable target to prevent CAVD. To test this hypothesis, we assessed the interaction of 5-HT(2B) antagonism with canonical and non-canonical TGF-β1 pathways to inhibit TGF-β1-induced activation of isolated porcine AVICs in vitro. Here we show that AVIC activation and subsequent calcific nodule formation is completely mitigated by 5-HT(2B) antagonism. Interestingly, 5-HT(2B) antagonism does not inhibit canonical TGF-β1 signaling as identified by Smad3 phosphorylation and activation of a partial plasminogen activator inhibitor-1 promoter (PAI-1, a transcriptional target of Smad3), but prevents non-canonical p38 MAPK phosphorylation. It was initially suspected that 5-HT(2B) antagonism prevents Src tyrosine kinase phosphorylation; however, we found that this is not the case and time-lapse microscopy indicates that 5-HT(2B) antagonism prevents non-canonical TGF-β1 signaling by physically arresting Src tyrosine kinase. This study demonstrates the necessity of non-canonical TGF-β1 signaling in leading to pathologic AVIC differentiation. Moreover, we believe that the results of this study suggest 5-HT(2B) antagonism as a novel therapeutic approach for CAVD that merits further investigation.

    Topics: Actins; Animals; Aortic Diseases; Aortic Valve; Calcinosis; Cell Differentiation; Cells, Cultured; Gene Expression; Indoles; Microfilament Proteins; Muscle Proteins; Myofibroblasts; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Plasminogen Activator Inhibitor 1; Promoter Regions, Genetic; Protein Processing, Post-Translational; Protein Transport; Pyridines; Receptor, Serotonin, 5-HT2B; Serotonin 5-HT2 Receptor Antagonists; Signal Transduction; Smad3 Protein; src-Family Kinases; Sus scrofa; Transcriptional Activation; Transforming Growth Factor beta1; Urea

2012